Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31256Editorial articleПередовая статьяResearch ArticleA possibility to interchange heart rate-slowing therapy with ivabradine and atenolol in patients with stable angina pectorisВозможность взаимозамены урежающей пульс терапии ивабрадином и атенололом у больных стабильной стенокардиейShavarovA AШаваровА Аshavarov@yahoo.comKiiakbaevG KКиякбаевГ КKobalavaZh DКобалаваЖ ДРоссийский университет дружбы народов, Москва15042013854VOL 85, NO4 ()ТОМ 85, №4 (2013)778310042020Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31256

AIM: To evaluate the efficiency and safety of an interchange of atenolol and ivabradine in patients who had stable angina pectoris without myocardial infarction in the history and left ventricular (LV) systolic dysfunction/MATERIAL AND METHODS: The trial enrolled 31 patients less than 70 years of age who had sinus rhythm, functional classes II-I angina on exertion without clinical signs of LV systolic dysfunction. At the first stage, 15 patients were randomized to ivabradine with its dose titration during 2 weeks; the other 16 patients were to atenolol. At the second stage, 10 patients were switched from ivabradine used at Stage 1 to atenolol 100 mg/day, other 10 patients who were on atenolol were switched to ivabradine 15 mg/day, and 11 patients received combination therapy with ivabradine + atenolol in half doses. All the patients underwent treadmill exercise testing and applanation tonometry/RESULTS: Atenolol, unlike ivabradine, lowered brachial blood pressure and unchanged the central index of its increment, which was associated with LV systolic elongation. On the contrary, ivabradine decreased the central increment index and exerted no significant effect on the duration of LV systole. By comparatively lowering heart rate, ivabradine as well as atenolol reduced pulse wave propagation velocity/CONCLUSION: If ivabradine or atenolol is insufficiently effective or poorly tolerated, there may be an interchange of the drugs, as well as their combination in half doses without substantially affecting their therapeutic action in patients with stable angina pectoris without LV systolic dysfunction.

Резюме. Цель исследования. Оценка эффективности и безопасности взаимозамены атенолола и ивабрадина у больных стабильной стенокардией без инфаркта миокарда в анамнезе и систолической дисфункции левого желудочка (ЛЖ). Материалы и методы. В исследование включили 31 пациента моложе 70 лет с синусовым ритмом, стенокардией напряжения II-III функционального класса без клинических признаков систолической дисфункции ЛЖ. На первом этапе 15 больных рандомизировали к приему ивабрадина с титрованием дозы в течение 2 нед, других 16 пациентов - к приему атенолола. На втором этапе у 10 больных, получавших на первом этапе ивабрадин, заменили атенололом в дозе 100 мг/сут, у 10 больных, получавших атенолол, его заменили ивабрадином в дозе 15 мг/сут, а 11 больных получали комбинированную терапию ивабрадин + атенолол в половинных дозах. Всем больным проводили тредмил-тест и аппланационную тонометрию. Результаты. Атенолол в отличие от ивабрадина, снижал уровень артериального давления на плечевой артерии и не изменял центральный индекс его прироста, что было сопряжено с удлинением систолы ЛЖ. Ивабрадин, напротив, снижал центральный индекс прироста и не оказывал значимого влияния на продолжительность систолы ЛЖ. Ивабрадин, как и атенолол, при сопоставимом снижении частоты сердечных сокращений уменьшал скорость распространения пульсовой волны. Заключение. У больных стабильной стенокардией без систолической дисфункции ЛЖ при недостаточной эффективности или плохой переносимости ивабрадина либо атенолола возможны взаимозамена препаратов, а также их комбинация в половинных дозах без существенного влияния на терапевтическое действие.

ivabradineatenololangina on exertionarterial stiffnesscentral blood pressureивабрадинатенололстенокардия напряженияартериальная жесткостьцентральное артериальное давлениеMarquis-Gravel G., Tardif J.C. Ivabradine: the evidence of its therapeutic impact in angina. Core Evidence 2008; 3 (1): 1-12.Tardif J.C., Ford I., Tendera M. et al. INITIATIVE investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-2525.Tardif J.C., Ponikowski P., Kahan T. for the ASSOCIATE study Investigators. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540-548.McMurray J., Alain Cohen-Solal A., Dietz R. et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. Eur J Heart Fail 2005; 7: 710-721.Bronstein A.C., Spyker D.A., Cantilena L.R. Jr et al. 2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report. Clin Toxicol (Phila) 2008; 46 (10): 927-1057.Ruzyllo W., Tendera M., Ford I., Fox K.M. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007; 67 (3): 393-405.Fox K., Garcia M.A.A., Ardissino D. et al. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27 (11): 1341-1381.Gayet J.L., Paganelli F., Cohen-Solal A. Update on the medical treatment of stable angina. Arch Cardiovasc Dis 2011; 104 (10): 536-544.Köster R., Kaehler J., Meinertz T. REDUCTION Study Group. Treatment of stable angina pectoris by ivabradine in every day practice: the EDUCTION study. Am Heart J 2009; 158 (4): e51-57.Borer J.S., Fox K., Jaillon P., Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003; 107: 817-823.Heusch G., Skyschally A., Gres P. et al. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J 2008; 29 (18): 2265-2275.Fox K., Ford I., Steg P.G. et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-816.Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55 (13): 1318-1327.Roman M.J., Devereux R.B., Kizer J.R. et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007; 50: 197-203.Pini R., Cavallini M.C., Palmieri V. et al. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol 2008; 51: 2432-2439.Williams B., Lacy P.S., Thom S.M. et al. for the CAFE and ASCOT investigators. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes. Circulation 2006; 113: 1213-1225.Jankowski P., Kawecka-Jaszcz K., Czarnecka D. et al. Aortic Blood Pressure and Survival Study Group. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension 2008; 51: 848-855.Safar M.E., Blacher J., Pannier B. et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: 735-738.Williams B., Lacy P.S. Central aortic pressure and clinical outcomes. J Hypertens 2009; 27: 1123-1125.Böhm M., Swedberg K., Komajda M. et al. SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomized placebo-controlled trial. Lancet 2010; 376 (9744): 886-894.Copie X., Hnatkova K., Staunton A. et al. Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two-year follow-up study. J Am Coll Cardiol 1996; 27: 270-276.Gillman M., Kannel W., Belanger A. et al. Influence of heart rate on mortality among persons with hypertension: The Framingham study. Am Heart J 1993; 125: 1148-1154.McAlister F.A, Wiebe N., Ezekowitz J.A. et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150 (11): 784-794.Teerlink J. Ivabradine in heart failure - no paradigm SHIFT yet. Lancet 2010; 376: 847-849.Steg P.G., Ferrari R., Ford I. et al. CLARIFY Investigators. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One 2012; 7 (5): e36284.Tashkin D.P. Β-blockers associated with reduced all-cause mortality in COPD. Evid Based Med 2012; 17: 31-32.